Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia

Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8.

Authors

Max J Gordon¹, Philipp W Raess², Kathleen Young¹, Stephen E F Spurgeon¹, Alexey V Danilov¹

Affiliations

¹ Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
² Department of Pathology, Oregon Health and Science University, Portland, OR, USA.

PMID: 27391978
DOI: 10.1111/bjh.14224

No abstract available

Keywords: cytogenetics; ibrutinib; prolymphocytic leukaemia.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Female
Humans
Male
Piperidines
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines / administration & dosage
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine